Quarterly report pursuant to Section 13 or 15(d)

SCHEDULE OF SEGMENT INFORMATION (Details)

v3.24.2.u1
SCHEDULE OF SEGMENT INFORMATION (Details) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Product Information [Line Items]        
Total net revenue $ 2,397,652 $ 19,738 $ 4,804,043 $ 20,659
Total operating loss (2,087,798) (1,778,350) (4,033,028) (3,336,320)
Non-operating income (expense), net (17,062) 42,764 (29,975) 79,763
Net loss before income tax expense (2,104,860) (1,735,586) (4,063,003) (3,256,557)
Income tax expense (5,419) (4,587) (9,091) (16,406)
Net loss (2,110,279) (1,740,173) (4,072,094) (3,272,963)
Diagnostic R&D [Member]        
Product Information [Line Items]        
Total net revenue 4,038 6,923
Total operating loss (453,895) (370,384) (896,494) (759,629)
Laboratory Services [Member]        
Product Information [Line Items]        
Total net revenue [1] 2,393,614 19,738 4,797,120 20,659
Total operating loss (2,535,285) (1,235) (5,272,284) (1,322)
General Corporate Activities [Member]        
Product Information [Line Items]        
Total operating loss $ (1,496,270) $ (1,426,469) $ (2,668,293) $ (2,596,028)
[1] The majority of the increase versus the prior year is from the acquisition of Precision Pathology Laboratories Services, LLC on September 18, 2023.